| Page 74 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

Author(s): 
Sallman DA, List A
Primary Author: 
Sallman DA
Journal Title: 
Blood
Original Publication Date: 
Jan 2019
In cancer biology, tumor-promoting inflammation and an inflammatory microenvironment play a vital role in disease pathogenesis. In the past decade, aberrant innate immune activation and proinflammatory signaling within the malignant
Bone Marrow Disease(s): 

A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes

Author(s): 
Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, Sallman D, Lancet JE, Tinsley S, Nardelli LA, Pinilla-Ibarz J, Epling-Burnette PK, List AF.
Primary Author: 
Komrokji RS
Journal Title: 
Clin Lymphoma Myeloma Leuk
Original Publication Date: 
Mar 2019
BACKGROUND:
Bone Marrow Disease(s): 

Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria.

Author(s): 
Escalante CP, Chisolm S, Song J, Richardson M, Salkeld E, Aoki E, Garcia-Manero G.
Primary Author: 
Escalante CP
Journal Title: 
Cancer Med
Original Publication Date: 
Feb 2019
BACKGROUND:
Bone Marrow Disease(s): 

Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia

Author(s): 
Xu ZL, Zhou M, Jia JS, Mo WJ, Zhang XH, Zhang YP, Wang Y, Li YM, Huang XJ, Wang SQ, Xu LP
Primary Author: 
Xu Zi
Journal Title: 
Bone Marrow Transplant
Original Publication Date: 
Jan 2019
Our study aimed to compare treatment outcomes between hematopoietic stem cell transplantation (HSCT) from haploidentical donors (HID) and immunosuppressive therapy (IST) in adults with acquired severe
Bone Marrow Disease(s):